These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27276707)

  • 1. Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.
    Broséus J; Chen G; Hergalant S; Ramstein G; Mounier N; Guéant JL; Feugier P; Gisselbrecht C; Thieblemont C; Houlgatte R
    Oncotarget; 2016 Dec; 7(51):83987-84002. PubMed ID: 27276707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
    Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
    J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.
    Guo L; Lin P; Xiong H; Tu S; Chen G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):85-96. PubMed ID: 29337112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
    Intlekofer AM; Joffe E; Batlevi CL; Hilden P; He J; Seshan VE; Zelenetz AD; Palomba ML; Moskowitz CH; Portlock C; Straus DJ; Noy A; Horwitz SM; Gerecitano JF; Moskowitz A; Hamlin P; Matasar MJ; Kumar A; van den Brink MR; Knapp KM; Pichardo JD; Nahas MK; Trabucco SE; Mughal T; Copeland AR; Papaemmanuil E; Moarii M; Levine RL; Dogan A; Miller VA; Younes A
    Blood Cancer J; 2018 Jun; 8(6):60. PubMed ID: 29895903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
    Peng W; Wu J; Feng J
    Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
    Modvig L; Vase M; d'Amore F
    Br J Haematol; 2017 Oct; 179(1):75-82. PubMed ID: 28653321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
    Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
    Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
    de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
    Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.
    Krzeminski P; Corchete LA; García JL; López-Corral L; Fermiñán E; García EM; Martín AA; Hernández-Rivas JM; García-Sanz R; San Miguel JF; Gutiérrez NC
    Oncotarget; 2016 Dec; 7(49):80664-80679. PubMed ID: 27811368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.
    Kreisel F; Kulkarni S; Kerns RT; Hassan A; Deshmukh H; Nagarajan R; Frater JL; Cashen A
    Cancer Genet; 2011 Mar; 204(3):129-37. PubMed ID: 21504712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
    Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
    Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.
    Juskevicius D; Lorber T; Gsponer J; Perrina V; Ruiz C; Stenner-Liewen F; Dirnhofer S; Tzankov A
    Leukemia; 2016 Dec; 30(12):2385-2395. PubMed ID: 27198204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
    Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
    Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.